Clinical Trial Update: A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1) [Phase 2]

View source ↗

Summary

The Phase 2b trial evaluating the fixed-dose combination of daclatasvir and sofosbuvir for non-cirrhotic, treatment-naive hepatitis C patients (genotypes 1-4) c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daklinza (Daclatasvir)
• Sovaldi (Sofosbuvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 2 | Status: WITHDRAWN